leukemia etoposid nsc complet respons CR patient acut nonlymphocyt leukemia anll singl agent etoposid combin cytarabin daunorubicin amsacrin salvag consolid therapi untreat anll patient year age day daunorubicin day drug etoposid day CR consolid cours attenu elig patient CR rate therapi CR rate therapi remiss durat median month month surviv analysi patient year age prolong remiss median month month surviv median month month regimen hematolog toxic similar regimen induct sever consolid therapi etoposid activ anll prolong remiss induct therapi 